Phase 3
Completed N=396
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
Hypertension, Pulmonary
Source: ClinicalTrials.gov NCT00863681 ↗
Enrolled (actual)
396
Serious AEs
69.7%
Results posted
Oct 2020
Primary outcomePrimary: Number of Participants With Treatment-emergent Adverse Events (TEAE) — 229; 108; 56; 138 Participants
◆ Published Evidence
Highly cited
140citations · ~14 / year
Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
Summary
Patients who have completed the 12 weeks treatment of the PATENT-1 trial (study number 12934) will be asked to participate in this long term extension study with BAY63-2521.
Linked Publications (5)
-
Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
-
Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.
-
Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.
-
Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
-
Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Treatment-emergent Adverse Events (TEAE) |
229; 108; 56; 138; 74; 30 | — |
| PRIMARY Number of Participant With Death |
48; 30; 7 | — |
| SECONDARY Percentage of Participants With Treatment-emergent High Laboratory Abnormalities in Hematology and Coagulation |
68.1; 80.0; 79.2; 1.0; 1.1; 2.0 | — |
| SECONDARY Percentage of Participants With Treatment-emergent Low Laboratory Abnormalities in Hematology and Coagulation |
12.8; 13.5; 8.5; 31.0; 22.8; 25.0 | — |
| SECONDARY Percentage of Participants With Treatment-emergent High Laboratory Abnormalities in Clinical Chemistry |
13.4; 12.0; 8.7; 0.5; 1.0; 0.0 | — |
| SECONDARY Percentage of Participants With Treatment-emergent Low Laboratory Abnormalities in Clinical Chemistry |
0.0; 0.0; 0.0; 4.1; 4.0; 0.0 | — |
Eligibility Criteria
Inclusion Criteria
- Patients who have completed 12 weeks of treatment in the double blind trial PATENT 1
Exclusion Criteria
- Patients who have an ongoing serious adverse event from PATENT 1 that is assessed as related to BAY63-2521 are not allowed to participate in the extension trial.
Data sourced from ClinicalTrials.gov (NCT00863681) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.